Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Discover how Semaglutide helped me lose 120 pounds and transform my life. A personal, honest look at the ups, downs, and what really worked.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to ...

In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide.